Cediranib
- Generic Name
- Cediranib
- Drug Type
- Small Molecule
- Chemical Formula
- C25H27FN4O3
- CAS Number
- 288383-20-0
- Unique Ingredient Identifier
- NQU9IPY4K9
Overview
The novel indole-ether quinazoline Cediranib is a highly potent (IC < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.
Background
The novel indole-ether quinazoline Cediranib is a highly potent (IC < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.
Indication
For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors.
Associated Conditions
No associated conditions information available.
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.